CBER’s Goal To Reach Normal Ops In 2023 Includes Clearing IND, Meeting Backlogs In 2022

 
• By Derrick Gingery

CBER director Peter Marks also wants to work on rare disease gene therapy issues and increase hiring before the end of the year.

backlog and stacks of paper
CBER wants to reduce the IND backlog in its Office of Vaccines Research and Review before the start of 2023. • Source: Shutterstock

More from Rare Diseases

More from Pink Sheet